Trial Profile
A Phase 1, Pharmacokinetic Study of STA-9090 in Combination With Docetaxel in Subjects With Advanced Solid Tumor Malignancies
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2014
Price :
$35
*
At a glance
- Drugs Ganetespib (Primary) ; Docetaxel
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Synta Pharmaceuticals
- 04 Jun 2012 Updated results were presented at the 48th Annual Meeting of the American Society of Clinical Oncology, according to a Synta Pharmaceuticals media release.
- 17 May 2012 Updated results will be presented at ASCO-2012 according to a Synta Pharmaceuticals media release.
- 27 Sep 2011 Results were presented at the European Multidisciplinary Cancer Congress (ECC-ESMO) in September 2011.